Novavax, Inc. NVAX
10.69 USD -0.09 (-0.88%)
Nov 9, 2026, 9:36 AM EST
10.61 Day range 10.86
6.20 52-week range 13.39
- YTD
- +59.00%
- 1 year
- +43.62%
News
benzinga.com B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16 B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 to $16.
marketbeat.com Novavax Q3 Earnings Call Highlights Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone…
zacks.com Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.
benzinga.com Novavax Raises FY2026 Sales Guidance from $235.000M-$275.000M to $385.000M-$415.000M vs $380.285M Est Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $235.000 million-$275.000 million to $385.000 million-$415.000 million vs $380.285 million estimate.
prnewswire.com Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D…
benzinga.com Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid Novavax (NASDAQ:NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's…
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
benzinga.com Citigroup Maintains Sell on Novavax, Raises Price Target to $8 Citigroup analyst Geoff Meacham maintains Novavax (NASDAQ:NVAX) with a Sell and raises the price target from $7 to $8.
benzinga.com Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
benzinga.com A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
benzinga.com Transcript: Novavax Q2 2026 Earnings Conference Call Novavax (NASDAQ:NVAX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time…
benzinga.com Novavax Stock Falls Back: What's Going On? Novavax is pulling back Tuesday after surging more than 20% Monday. Vaccine stocks rallied on a suspected pneumonic plague case in Russia.
benzinga.com Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose…
benzinga.com Novavax, Nvidia, MercadoLibre, Nu Holdings and PTC: Why These 5 Stocks Are on Investors' Radars Today NVAX, NVDA, MELI, NU, PTC were among the stocks seen trending on Monday, Oct. 5, 2026.
benzinga.com Novavax Shorts on Edge as Russia Plague Fears Spread Unconfirmed plague fears sent Novavax up 24% in a potential short squeeze, lifting vaccine stocks despite no clear link to its products.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor Novavax is rising on investors reaction to an unconfirmed rumor that Matrix-M has a favorable safety profile with self-limiting side effects.
benzinga.com What's Going On With Novavax Stock? Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot…
benzinga.com Novavax Stock Climbs Monday: What's Going On? Shares of Novavax are trading higher Monday, extending its 30% monthly gains on COVID-19 vaccine approvals and broader biotech strength.
benzinga.com Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc.…
benzinga.com Novavax's Partners Receive Approvals For Nuvaxovid Formulation To Target SARS-CoV-2 XFG Variant Novavax, Inc.'s (NASDAQ:NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the…
benzinga.com QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
benzinga.com Novavax Stock Rallies Tuesday: What's Happening? Shares of Novavax are trading higher Tuesday morning as buying interest continues across late-stage vaccine developers.
benzinga.com Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
benzinga.com Novavax Stock Moves Higher Wednesday: What's Driving the Action? Shares of Novavax Inc (NASDAQ: NVAX) are trading higher Wednesday. The move comes as a major clinical victory in the oncology space generated widespread momentum across vaccine developers.
benzinga.com Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children https://youtu.be/H_RititNE8U- benzinga.com Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M Est Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $230.000 million-$270.000 million to $235.000 million-$275.000 million vs $389.234 million estimate.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby, CoreWeave, Salesforce, Lucid and more.
benzinga.com Why Is Pfizer Stock Rising Tuesday? Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for…
benzinga.com Novavax Stock Is Surging Monday: What's Driving The Action? Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.
benzinga.com AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto…
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Top Stocks With Earnings This Week: Joby, IonQ, AMD and More Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
benzinga.com La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public…
benzinga.com US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says Expert U.S. stock futures were slightly lower on Tuesday after ending largely flat on Monday. Futures of major benchmark indices were trading lower in premarket.- benzinga.com Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.
benzinga.com CI&T, Novavax, Paramount Group And Other Big Stocks Moving Higher On Monday 
benzinga.com Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket 
benzinga.com US Stocks Likely To Open Lower After Moody's Downgrade: 'Bear Market Isn't Fully Recovered Yet, But It Is Close,' Says Expert U.S. stock futures dipped on Monday after closing higher for the day and the week on Friday. Futures were trading lower in premarket.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Earnings Scheduled For May 8, 2025
benzinga.com Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.- benzinga.com 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics